Alexion uses priority review voucher for Soliris follow-up

Alexion uses priority review voucher for Soliris follow-up. Files ravulizumab for paroxysmal nocturnal haemoglobinuria. ... Alexion is pulling out all the stops to get speedy approval for a follow-up to its rare blood disorder therapy Soliris, using a

Morning brief: Sanofi's shaky start, pharma begins talks with UK government and more

gMG). It also unveiled positive top-line data from its Phase III trial of ALXN1210, a long-acting form of its flagship treatment Soliris. ... ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH) need only be administered once every eight

Alexion adds to pipeline rebuild with $855m Wilson buy

Alexion Pharma’s drive to reduce its reliance on cash cow Soliris has gone up a gear with a $855m offer for rare disease company Wilson Therapeutics. ... has a long way to go before it bears comparison with Soliris’$3.1bn turnover.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 (Next 4)